Strategic Partnership with BioNTech for PD-L1 VEGF Bispecific BNT327
BMS entered into a global strategic partnership with BioNTech to co-develop and commercialize BNT327, a potentially transformative PD-L1 VEGF bispecific therapy.
The collaboration aims to accelerate clinical trials, expedite time to market, and expand indications, with the goal of positioning BNT327 as a first or second to market in its class.
The partnership leverages BMS' expertise in immuno-oncology and BioNTech's innovation, with a focus on speed to market and broadening indications.
Initial clinical development is underway in small cell lung cancer, non-small cell lung cancer, and triple-negative breast cancer.
Recognition of Top-Ranked Rehabilitation Hospitals and Strategic Development Achievements
Eight hospitals recognized among the nation's best by U.S. News & World Report, with Kessler Institute for Rehabilitation ranked #4 for 33rd consecutive year.
Opened new facilities including a 12-bed hospital with UPMC in Pennsylvania, a neuro transitional care unit in Missouri, and expansions in Florida.
Plans to open multiple new hospitals in 2026 and 2027, including partnerships with Banner Health and Cox Health Systems, with a focus on high-demand markets.
Commercial Transformation and Sales Process Overhaul
The commercial transformation aims to capitalize on large enterprise and IDN opportunities, with a focus on moving from early-stage to later-stage deals.
The company has retooled its sales team to target hospital CNOs and other key decision-makers, emphasizing change management and clinical benefits.
Progress includes a more disciplined approach to sales forecasting, pipeline management, and deal closure, setting the stage for sustained growth.
Dafinchi
